RVX is planning a P2 PAH study after recently announcing the successful pilot PAH study at Laval University (I think it was Laval). Acceleron just started sharing P2 data for their PAH canadidate, sotatercept, so they are ahead from a timeline perspective. Acceleron also has revenues in excess of $100M/quarter from Reblozyl. I’m not sure Don can spell revenue. Perhaps though if the covid trial goes ahead and works out, RVX and Zenith could be packaged up and sold off together for that kind of money or maybe even more. I still think there is a good future for epigenetics and I still believe RVX and Zenith together would provide a great epigenetics platform for some BP to explore and exploit for years to come.